Dental nonsteroidal anti-inflammatory drugs and prostaglandin-based drug interactions, Part two.
Dental School, University of Maryland at Baltimore.
R L
RL
Wynn
D000319:Adrenergic beta-Antagonists / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000037:antagonists & inhibitors*; D001581:Benzothiadiazines; D001714:Bipolar Disorder; D000075202:Contraindications; D003730:Dental Care for Persons with Disabilities; D004232:Diuretics; D004336:Drug Antagonism; D005665:Furosemide / Q000037:antagonists & inhibitors; D006801:Humans; D006973:Hypertension; D016651:Lithium Carbonate / Q000037:antagonists & inhibitors*; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D012559:Schizophrenia; D049993:Sodium Chloride Symporter Inhibitors / Q000037:antagonists & inhibitors*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D011448:Prostaglandin Antagonists; D049993:Sodium Chloride Symporter Inhibitors; D016651:Lithium Carbonate; D005665:Furosemide